CB1 Capital Management predicts Cannabis could disrupt the healthcare industry in a big way. The firm's Founding Partner and Chief Investment Officer Todd Harrison explains why he thinks medical marijuana will migrate from state dispensaries, to become medicine prescribed by doctors through insurance in the next decade.
Harrison says the only way the U.S. government would get their hands on the money in this market opportunity is through the FDA. "That's where we think it goes, follow the money," says Harrison.
"This is not so much a trade about commerce, as it is a trade about healthcare," said Harrison. "We think that this is going to migrate towards medicine." One of CB1 Capital Management's holdings GW Pharmaceuticals is up 30 percent over the past three months. Harrison expects this company to publish research showing the efficacy of cannabis treatment this summer.
The U.S. Supreme Court unanimously decided Monday to restore former president Donald Trump to 2024 presidential primary ballots. The court Monday rejected state attempts to hold the Republican former president accountable for the Capitol riot.
Voyager Ventures founding partners Sarah Sclarsic and Sierra Peterson discuss how they choose products and companies to invest in, and why there’s such high demand for sustainable tech.
